Denali Therapeutics appoints Erik Harris to Board of Directors

Denali Therapeutics Inc.

Erik Harris appointed to Board and Audit Committee effective Feb 3, 2022, as Class II director.
Annual cash compensation of $45,000 for Board service, plus $10,000 for Audit Committee.
Initial equity awards valued at ~$700,000 aggregate (60% option, 40% RSU) with 4-year vesting.
Harris is Chief Commercial Officer and EVP at Ultragenyx, with 20 years biotech commercial experience.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Erik Harris

Director

DNLI · Denali Therapeutics Inc.

Effective: 2022-02-03
Filed: February 7, 2022, 6:59 PM ET

On February 3, 2022, Erik Harris was appointed to the Board of Directors (the “Board”) and to the Audit Committee of the Board (the "Audit Committee") of Denali Therapeutics Inc. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Erik Harris was appointed as Director at Denali Therapeutics Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 3, 2022, Erik Harris was appointed to the Board of Directors (the “Board”) and to the Audit Committee of the Board (the "Audit Committee") of Denali Therapeutics Inc. (the “Company”).

View on SEC.gov

Denali Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001714899-22-000021

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.